Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients With EBV-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Trial Profile

Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients With EBV-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Epstein-Barr virus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Gastric cancer; Haemophagocytic lymphohistiocytosis; Leiomyosarcoma; Lymphoma; Lymphoproliferative disorders; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder; Viraemia
  • Focus Expanded access; Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 10 Aug 2017 According to an Atara Biotherapeutics media release, multicenter data from this clinical study is expected to be presented at appropriate future scientific conferences.
    • 12 Jul 2016 According to Atara Biotherapeutics media release, company announced the dosing of first patient in this trial.
    • 01 Jul 2016 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top